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Summary 
Nucleic acid sequences can produce a wide variety of three-dimensional conformations. Some of these structural 
forms are able to interact with proteins and small molecules with high affinity and specificity. These sequences, 
comprising either double or single stranded oligonucleotides, are called “aptamers” based on the Greek word aptus, 
which means “to fit”. Using an efficient selection process, randomised oligonucleotide libraries can be rapidly 
screened for aptamers with the appropriate binding characteristics. This technology has spawned the development 
of a new class of oligonucleotide therapeutic products. However, while interest among pharmaceutical companies 
continues to grow with some candidates already in clinical trials and one in the market, there appears to be some 
reluctance to fully explore the diagnostic potential of this technology. This article will review aptamer developments 
in diagnostics, compare them with other oligonucleotide therapeutics and highlight both potentials and pitfalls of 
technological development in this area. 
 
 
I. Introduction 
Advances in genomic and proteomic technology have 
allowed the identification of genes and/or gene products 
involved in the development and progression of cancer. 
This, in turn, has facilitated the development of novel drug 
compounds, leading to a variety of molecules showing 
promising therapeutic and diagnostic potential as anti-
cancer agents. Such molecules include small compounds, 
peptides, antibodies and more recently oligonucleotides. 
Apart from their role in the evolutionary archives of 
life, the use of DNA and RNA as natural ligands in 
evading cellular defence mechanisms was first discovered 
in the late 1970’s with their application in antisense 
therapy. In this approach, the synthesis of disease-related 
proteins is disrupted by blocking the expression of their 
encoding mRNA. This is achieved by using 
complementary single stranded nucleic acids to hybridise 
in a sequence-dependent manner to the target mRNA. In 
this way, inhibition at the genetic level (and therefore 
protein production) occurs by the steric blockage of 
ribosomal scanning of the mRNA or by the activation of 
endogenous ribonuclease H (RNase H) (Younes et al, 
2002; Famulok and Mayer, 2005). This simple approach to 
gene regulation, although promising, has vital limitations 
which hinder its wide scale application, as has been the 
case with other genetic manipulation strategies (for 
example, gene knockout and short interfering RNAs). For 
example, the target mRNA sequence may be inaccessible 
to the inhibiting oligonucleotide as other proteins may pre-
occupy the binding sequence (Famulok and Mayer, 2005). 
Most proteins are found to operate as part of a multi-
protein complex. Hence, completely abolishing the 
production of a protein may incur secondary effects on the 
complexes function (Thompson et al, 2002; Blank and 
Blind, 2005). In addition, for in vivo applications, the 
intracellular target is often difficult to access due to the 
low permeability of the oligonucleotide through the cell 
membrane (Pestourie et al, 2005). Despite these 
drawbacks, the use of oligonuclotides as therapeutic and 
diagnostic agents has however been explored further, 
where they are applied to function at the proteomic rather 
than the genetic level. Discovered around 15 years ago 
(Ellington and Szostak, 1990; Tuerk and Gold, 1990), 
aptamers offer an exciting prospect in their application as 
a novel class of nucleic acid inhibitors/ligands. Aptamers 
are short, single stranded oligonucleotides which 
inherently adopt stable three dimensional sequence-
dependent structures. This intrinsic property makes them 
efficient binding molecules, such that they are capable of 
binding to an array of molecular targets ranging from 
small ions and organic molecules to large glycoproteins 
and mucins. Aptamers are typically isolated from 
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combinatorial libraries by a process of in vitro evolution, 
termed SELEX. These novel oligonucleotides exhibit high 
specificity and affinity for their target, in addition to often 
having high inhibitory potential. Additionally, aptamers 
are easily modified, making them valuable molecules for 
the delivery of therapeutic agents and/or for imaging and 
clinical diagnosis. Consequently, this technology, now 
approaching its second decade of development, shows 
considerable promise with two therapeutic aptamers in 
phase III trials and one already in the market. Relevant 
oncology targets are also attracting some interest, not least 
due to the potential benefits that aptamers have over 
antibody-based therapeutics. However, despite the 
advances and the huge body of literature documenting the 
success of the technology, the commercial application of 
aptamers in the field of diagnostics remains relatively 
undeveloped, not least due to the exclusive IP portfolio 
that prohibits potentially interested companies to invest in 
this area of research and development. Furthermore, there 
is already a significant antibody diagnostic market 
developed, and aptamers would need to offer significant 
improvements on current technologies to warrant the 
substitution of antibodies in current assay formats. 
 
A. Selection of aptamers by the 
traditional method of SELEX 
The generation of aptamers towards a specific target 
is typically achieved through a process called SELEX 
(Systematic Evolution of Ligands by EXponential 
enrichment). This procedure can be considered as an in 
vitro evolutionary selection process which allows the 
isolation of aptamer(s), with unique binding properties, 
from a large library of oligonucleotides. The core of the 
SELEX procedure consists of iterative cycles of two steps 
(i) selection of aptamers having an affinity to the target 
and (ii) amplification of the binding aptamers (Figure 1). 
The starting point of SELEX begins with the 
synthesis of a combinatorial library of single stranded 
nucleic acids. The oligonucleotides synthesised for the 
library usually consist of a central region of variable base 
sequence (20-40 nucleotides) flanked by regions of known 
sequences on either end. The flanking sequences act as 
primers for amplification during the SELEX procedure. 
Typically, libraries contain up to 1015 different sequences 
which, combined with the innate ability of 
oligonucleotides to form stable sequence-dependent
 
 
Figure 1. Schematic representation of a typical SELEX process 
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structures, provide an array of molecular shapes available 
for the selection process. In the selection steps, the library 
is initially incubated with the immobilised target under 
conditions which would mimic the in vivo application of 
the binding aptamers (e.g. physiological conditions). 
Subsequently, non- or weak-binding sequences are 
removed and those nucleic acids which adopt 
conformations that favour their binding to the target are 
eluted. Effective partitioning of the binding aptamers from 
the non-binding species can be achieved by methods such 
as affinity chromatography, nitrocellulose filtration, and 
magnetic functionalised beads. The binding nucleic acids 
are subsequently amplified by PCR (DNA) or reverse-
transcription PCR (RNA) using primers complementary to 
the flanking sequences in the nucleic acid library. The 
enriched pool of binding oligonucleotides then acts as the 
library for the next round of selection. By repeating the 
selection and amplification steps iteratively, the library of 
oligonucleotides becomes less complex owing to 
competitive binding. However, the amplification process 
is susceptible to producing mutations, which can further 
add to the variability in the number of sequences available 
for binding. The selection and amplification step is 
referred to as one round or cycle and a typical SELEX 
procedure requires 8-12 cycles for the isolation of nucleic 
acids which have the highest affinity to the target, though 
as little as 1 cycle have been performed. To enhance the 
specificity of aptamers, some researchers incorporate 
additional “negative selection” steps at any stage in the 
SELEX process. In such steps, the aptamers recovered 
(and amplified) from any given round are incubated with 
variants/isoforms of the target of interest, and the nucleic 
acids which do not bind are now selected and amplified. 
Using this additional step ensures that the aptamers 
selected at the end of the SELEX experiment are able to 
discriminate (and therefore unlikely to cross react in vivo) 
between proteins which have similar conformations or 
properties to the target of interest. 
Selected aptamers from the last round of SELEX are 
subsequently cloned, sequenced and characterised for their 
ability to bind to the target, possibly inhibiting its function, 
and for their application in vivo. Following sequence 
identification, the selected aptamer can be easily produced 
by chemical or enzymatic synthesis. Furthermore, 
additional chemical modifications can be easily made, at 
desired positions of the aptamer, to improve its therapeutic 
and/or diagnostic application. For example, given their 
susceptibility to nucleases, aptamers have often been 
found to be unstable in biological fluids, thus limiting their 
therapeutic applicability. However, modifications made to 
the backbone of these oligonucleotides (mainly at the 2' 
ribonucleotide position) have shown to significantly 
increase their plasma stability (Dougan et al, 2000; 
Darfeuille et al, 2004; Yan, 2004). Alternatively, to 
overcome degradation by nucleases, mirror-image (L-
DNA/RNA) aptamers, termed spiegelmers, have recently 
been employed (Eulberg and Klussmann, 2003). 
Spiegelmers are isolated using typical SELEX methods, 
where a standard aptamer library is used to bind to the 
enantiomer form of the desired target. The isolated 
aptamer(s) is then synthesised as L-oligonucleotide which, 
in principle and largely in practice, binds to the 
physiological form of the target. While spiegelmers lose 
their susceptibility towards endogenous nucleases, they 
still bind to their target with the same affinity and 
specificity as the aptamer isolated for the enantiomer 
target (Williams et al, 1997; Leva et al, 2002). 
Spiegelmers have been isolated to bind to D-adenosine 
(Klussmann et al, 1996), vasopressin (Floege et al, 1999) 
and GnRH I (gonadotropin releasing hormone). 
Antagonists to GnRH I may have important implications 
into the treatment of hormone related benign and 
malignant tumours (Leva et al, 2002). 
Other modifications made to aptamers include 
attachments of large hydrophilic and hydrophobic moieties 
such as PEG (Floege et al, 1999) or liposomes, 
respectively. Attachments of such molecules serve to 
decrease the renal clearance time of aptamers, as the 
pharmacokinetic properties of these molecules are limited 
by their small size (5-25 KDa). Signalling molecules such 
as fluorophores can also be incorporated into the aptamer 
for imaging/signalling purposes, while the attachment of 
drugs can facilitate the therapeutic effect of the aptamer, if 
required (Floege et al, 1999). Although chemical 
modifications can be completed relatively easily, it is 
important that such alterations to the backbone structure of 
the aptamer do not affect its binding to the target, 
particularly given that binding is largely governed by 
shape-shape interactions between the two molecules. 
Consequently, once modified, the aptamers need to be re-
tested for their specificity/affinity towards the target. 
Modifications to the aptamer can sometimes be a daunting 
task if it leads to a decrease in the aptamers’ affinity or 
even completely hindering their binding to the target. 
Taking this into account, many researchers employ 
modifications to the aptamer library at the start of the 
SELEX process so that any alteration to the aptamer(s) 
selected, will be those that favour binding initially. 
However, this too poses problems in the amplification 
stages of the SELEX procedure, as the modified 
nucleotides must still be recognised by the enzyme (e.g. 
Taq polymerase) used in the PCR step and they increase 
the cost of the production of the molecules. This, in turn, 
initiated research to focus on engineering prospective 
modified oligonucleotides which can act as substrates for 
amplification enzymes or, alternatively, finding 
amplification enzymes with low substrate specificity, 
which has been done with some success. T7 RNA 
polymerase, for example, is able to recognise 2’-
fluoropyrimidine modified RNA, which has allowed the 
successful isolation of RNA aptamers for VEGF 
(Ruckman et al, 1998) and oncostatin M (Rhodes et al, 
2000) from modified libraries. Such aptamers have shown 
increased stability towards nucleases without significantly 
compromising their binding affinity and specificity 
towards their target. The utility of aptamer libraries with 
other modifications, such as the attachment of PEG, in 
standard SELEX methods, however, has yet still to be 
achieved. Equally, the evolution of non-SELEX methods 
has potentially overcome the limitations associated with 
the use of modified aptamer libraries and may open the 
market in diagnostic applications by offering alternatives 
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to the SELEX patented technology that has limited their 
development in the past years. 
 
B. Non-SELEX methods for the selection 
of aptamers 
SELEX has undoubtedly proved to be a very robust 
and powerful method in allowing the isolation of many 
aptamers directed towards desired targets. However, 
modern science has improved on this technique by 
developing methodologies which overcome some of the 
drawbacks associated with traditional SELEX procedures. 
Apart from making automated robotic systems to improve 
the efficiency of traditional SELEX, other “non-SELEX” 
based methods for the selection of aptamers have recently 
been put into practice. The utilisation of capillary 
electrophoresis has been shown to be a highly efficient 
approach for the partitioning of aptamers with desired 
properties from a randomised pool (Drabovich et al, 2005; 
Berezovski et al, 2005) (see also Krylov, 2006 for a 
review into capillary electrophoresis). Using this 
technique, aptamers to h-Ras, a protein involved in the 
development and progression of cancer, were isolated with 
predetermined kinetic parameters (Berezovski et al, 2005). 
The isolation of aptamers with predefined kinetic and 
thermodynamic properties of their interaction with the 
target has so far been obstructed by standard SELEX 
technology. Furthermore, this method of aptamer selection 
only employed the partitioning steps of SELEX without 
the need for amplification between them. Hence, one of 
the most significant advantages of this non-SELEX 
method is its application to libraries which are difficult or 
cannot be amplified, thus overcoming the problems 
associated with using modified oligonucleotide libraries, 
as mentioned above. As well as the relative simplicity and 
easy-to-use nature of this procedure, aptamers are selected 
within only a few hours, which contrasts the several days 
or weeks needed for standard SELEX systems. 
Exploitation of computational methods has also led 
the way into the development of non-SELEX methods for 
aptamer selection. More importantly, computational 
methods have been powerful in selecting aptamers with 
inhibitory activities or sequences that undergo ligand 
dependent conformational changes, a property useful for 
the design of molecular and aptamer beacons (see below). 
One of the major drawbacks associated with SELEX is the 
selection of aptamers that may not have any inhibitory 
activity towards its target, since the selection of aptamers 
is based on affinity. Consequently, researchers have used 
this drawback to drive the engineering of alternative 
selection methods based on inhibitory activity of aptamers. 
Algorithm methods have shown to be sufficiently 
effective in selecting aptamers with such properties 
(Ikebukuro et al, 2005). This computational method has 
been used to predict the secondary structure of nucleic 
acids under different conditions e.g. in the presence and 
absence of a ligand (Hall et al, 2006). In general, 
algorithmic methods use aptamers with known structures 
and/or features (such as aptamers that undergo ligand-
induced conformation changes) to rapidly select 
oligonucleotides from virtual pools which may present 
similar properties or adopt similar structures. Hence, 
sequences are selected that match a defined profile. One of 
the most valuable structures applied to computational 
selection is that of the G-quartet. Such structures are 
suggested to have important implications in the biology of 
cancer and thus, aptamers which adopt such configurations 
are of intense interest. An aptamer selected for thrombin 
has been thoroughly investigated and is known to adopt 
such a configuration. Consequently, this aptamer has been 
used as a model to investigate the potential of new 
selection methods, based on inhibitory activity. By 
randomising the sequence of the duplex region of the anti-
thrombin aptamer, Ikebukuro and colleagues selected in 
2006 inhibitory aptamers using genetic algorithm on a 
library of limited sequences. In another report, evolution 
mimicking algorithms were used to select aptamers with 
potent inhibitory activity from a pool that was designed to 
form G-quartet structures and contain a limited number of 
sequences (Noma and Ikebukuro, 2006). Other reports 
have used the structure of aptamers that undergo ligand-
induced conformational changes as a basis for the 
selection of new aptamers that will effectively function as 
biosensors (Hall et al, 2006). Computational selection 
methods of aptamers require detailed information on the 
pre-requisites of the basis of selection e.g. the structure of 
the aptamer that new aptamers are to be modelled on or 
the structural changes that the profile aptamer undergoes 
upon ligand binding. Given that this is not always feasible 
and that gaining this information can sometimes be a 
lengthy process, computational selection of aptamers may 
be somewhat delayed. SELEX itself, however, is still 
widely used for aptamer selection and has advanced (and 
still is) rapidly to overcome many of its challenges. 
 
II. Aptamer like reagents 
The versatility of aptamers has greatly facilitated 
modern drug development. Based on the principal 
properties of aptamers, research into other novel 
compounds for diagnostic and therapeutic purposes has 
been progressively initiated. Consequently, many other 
aptamer-like reagents have evolved and are currently at 
the forefront of medical research with aptamers 
themselves. Such biomolecules are briefly described 
below in terms of their diagnostic and/or therapeutic 
potential. 
 
A. Aptamer like reagents for therapeutics 
1. Peptide aptamers 
Peptide aptamers can be described as molecules 
consisting of a peptide domain, with a high affinity for a 
target, integrated as part of a stable scaffold protein. The 
peptide domain of these novel aptamers are frequently 
selected from a peptide library, similar to aptamer 
libraries. A highly complex peptide library is conceived by 
synthesising random oligonucleotides encoding for 20mer 
peptides which can contain any of the 20 amino acids at 
any of the 20 positions. These diverse sequences are then 
cloned within the open reading frame region of a vector 
which encodes for a scaffold protein. This, consequently, 
allows for the peptide domain to be expressed directly as 
part of the scaffold protein. The most common scaffold 
protein used is the E. coli thioredoxin A protein (TrxA) 
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(Buerger et al, 2003; Borghouts et al, 2005). However, 
alternative scaffolds such as green fluorescent protein and 
the inactive derivative of staphylococcal nuclease 
(Klevenz et al, 2002; Martel et al, 2006) have also been 
successfully integrated into peptide aptamers. In contrast 
to other man-made proteins, where a random peptide 
sequence and a protein are fused via their terminal ends, 
the variable peptide sequence of peptide aptamers is 
inserted directly within the scaffold (Baines and Colas, 
2006). This use of scaffolds constrains the conformational 
freedom of the peptide domain, therefore forcing it to 
adopt a distinct three-dimensional shape. This 
conformational constraint has many advantages: (i) it 
renders the peptide aptamer less susceptible to proteases 
(ii) it aids in exposing amino acids which would otherwise 
be buried in flexible peptides and (iii) increases the 
binding efficacy of the peptide towards its target (Klevenz 
et al, 2002; Crawford et al, 2003). Selection of peptide 
aptamers that bind to a pre-determined target is commonly 
performed using a modified yeast two-hybrid assay (see 
Colas, 2000 and Hoppe-Seyler and Butz, 2000 for an 
overview). However, other methods such as phage 
displays and bacterial selection have also been employed 
(Colas, 2000). 
Peptide aptamers have shown to not only bind to 
their target protein, but also inhibit protein function 
directly (e.g. blocking the active site of an enzyme) or 
indirectly. For example, many proteins need to form 
dimers (homo- or hetero-dimers) to be active, or recruit 
other proteins (e.g. kinases, ras proteins) to mediate their 
function. Such interactions can be masked if the peptide 
aptamer binds to distinct domains within the protein target. 
Advantageously, peptide aptamers have a subtle inhibitory 
effect, since, by binding to a specific domain, only one 
property of the protein (in proteins with multifunctional 
domains) is inhibited, while others may remain intact 
(Borghouts et al, 2005). 
Peptide aptamers have been selected against a 
plethora of targets, including proteins involved in the 
development and progression of cancer. A peptide aptamer 
(pep8) has been shown to block cell cycle progression by 
competitively inhibiting the enzymatic activity of protein 
kinase Cdk2 (Cohen et al, 1998). The peptide aptamer 
KDI1 was selected to bind to the intracellular domain of 
EGFR, a protein involved in signalling cascades which 
lead to cell growth and proliferation. By binding to EGFR, 
this peptide aptamer suppressed EGFR-mediated 
signalling, thereby reducing the growth and metastasis of 
tumor cells (Buerger and Groner, 2003). The high 
expression of protein kinase CK2 in human cancers, and 
its involvement in tumorigenesis, has made this enzyme an 
attractive therapeutic target in cancer. Using a two-hybrid 
system approach, a peptide aptamer was selected to bind 
to protein kinase CK2, which furthermore showed to 
induce apoptosis in mammalian cells (Martel et al, 2006). 
The inhibition of cancer protein targets, and their 
downstream signalling events, highlights the therapeutic 
potential peptide aptamers hold. However, as with nucleic 
acid aptamers, these small molecules also have limitations 
that need to be addressed, such as their method of 
delivery, their low cell membrane permeability and their 
potential immunogenicity (Borghouts et al, 2005). 
Researchers within the peptide aptamer field are focusing 
on addressing these issues, but as yet these small drug 
molecules are still in their early years of development. 
 
2. Decoys 
Aptamers can also be used to function as decoys. 
Decoy molecules are short lengths of double stranded 
DNA or RNA. These oligonucleotides are synthesised so 
as to contain the same nucleotide sequence as part of the 
target gene. As a result, these molecules compete with the 
target gene for binding proteins which act as 
transcriptional activators. In this way, decoys attract away 
the transcription protein which would otherwise bind to 
the promoter of the target and activate transcriptional 
events (Opalinska and Gewirtz, 2002). While decoy 
oligonucleotides are designed so that they are made of the 
same nucleotide sequence as that of their target gene (or 
part of it), an alternative method used to inhibit translation 
or destabilise/destroy RNA employs the use of antisense 
technology: oligonucleotides with a sequence 
complementary to their target genes. The more recent 
approach in this field focuses on the use of catalytically 
active RNA and DNA for therapeutic (ribozymes, 
DNAzymes) and diagnostic use (aptazymes/riboreporters 
and molecular beacons). 
 
3. Antisense agents 
While aptamers are mainly generated to target 
proteins that are believed to be involved in causing 
diseases, the use of antisense agents is primarily to 
function at the genetic level of the disease and involves 
preventing mRNA transport, inhibition of mRNA splicing 
and inhibition of 5’ cap formation of mRNA, all of which 
prevent maturation of mRNA (Chan et al, 2006). By 
targeting the genetic cause of cancer, antisense molecules 
can effectively block the expression of a protein, a process 
that offers higher specificity than many protein-targeting 
therapies. For example, many enzymes belong to large 
families which share high sequence and structural 
homology, consequently making the ability of small 
therapeutic molecules to discriminate between individual 
members a difficult task. This is particularly important 
when one wants to inhibit the function of an enzyme 
which undertakes a reaction that is used widely by many 
enzymes. For example kinases are implied to have an 
important role in signalling pathways that ultimately lead 
to the development of many diseases. The function of 
these enzymes is to primarily phosphorylate other proteins 
leading to their activation or inactivation, a reaction which 
is an attractive target for many drug-like molecules. 
However, given that a large number of kinases exist (each 
having different targets), the ability to develop small drug 
molecules to isolate a specific kinase can be challenging. 
Consequently, many researchers have put considerable 
efforts into directly targeting the mRNA encoding for such 
proteins. Thus, a number of antisense oligonucleotides 
have currently entered clinical trials for a number of 
targets, both in oncology (Table 1) and for other diseases. 
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Table 1. Antisense oligonucleotides in clinical trials in oncology, with details on their target, trial phase and the companies 
that have developed them. 
 
Drug Target Phase Company 
OGX-011 Clusterin II ISIS and OncoGenex 
LY2181308 Survivin I ISIS and Lilly 
LY2275796 eIF-4E I ISIS and Lilly 
OGX-427 Hsp27 I ISIS and OncoGenex 
Oblimersen (genasense/G-
3139) 
Bcl-2 III Genta Inc. 
GTI-2040 Ribonucleotide reductase II Lorus 
GTI-2501 Ribonucleotide reductase II Lorus 
LErafAON-ETU c-raf I Neopharm 
AEG35156 XIAP II Aegera therapeutics 
AP12009 TGF- 2 II Antisense Pharma 
ISIS-2503 H-ras II NCI 
 
 
The use of traditional antisense oligonucleotides has 
now mostly been superseded by other types of antisense 
oligonucleotides, such as siRNA. First discovered in the 
late 90’s by Fire and Mello in 1998, RNA interference 
(RNAi) has since received considerable interest in its 
application as a powerful research tool and more 
importantly as a potent therapeutic. Their research in the 
nematode Caenorhabditis elegans, showed that naturally 
occurring dsRNA molecules effectively led to the down-
regulation of gene expression, for which they coined the 
term RNAi. Since then, this natural process for gene 
silencing has been observed in many organisms ranging 
from plants to humans (Cullen, 2002; Hannon, 2002). 
Acting at the post-transcriptional level, RNAi is a process 
whereby dsRNA molecules trigger the degradation of 
target mRNA by utilising two proteins conserved among 
all multicellular organisms. Hence, whilst the traditional 
antisense mechanism exploits the use of RNase H, RNAi 
differs by utilising Dicer, and primarily RISC, as a means 
to regulate gene expression. 
RNAi is a naturally occurring phenomenon; hence 
multicellular organisms contain innate dsRNA molecules 
to trigger RNAi. This highly conserved method of gene 
regulation is widely believed to be an evolutionary 
mechanism to protect the genome of organisms from 
invading pathogens such as virus’ and transposans and 
defective mRNAs (Cullen, 2002; Hannon, 2002). 
Scientists, however, have exploited this natural defence 
mechanism as a powerful therapeutic tool, by rationally 
designing short dsRNA molecules i.e. siRNAs and 
introducing them into cells to silence targeted genes. 
Transfection of larger dsRNAs (analogous to the 
endogenous ones that trigger RNAi) in mammalian cells 
often leads to activation of the innate immune response 
(interferon response) and cell death. siRNAs are typically 
21-25 nucleotides in length, with the antisense strand 
designed to be complementary to any target mRNA, hence 
these drugs can be used to treat a variety of diseases which 
involve alterations in gene expression patterns. Several 
papers have reported the successful transfection of 
chemically synthesised siRNAs into mammalian cells, 
which lead to the down regulation of target genes by 
RNAi. Although RNAi and siRNA drugs are still in their 
infancy, they are considered to be one of the strongest 
candidates, among antisense and other types of drug 
molecules, for the future treatment of a range of diseases 
including infection, neurodegenerative diseases and 
cancer. 
A number of therapeutic approaches have been 
adopted with siRNAs. Using liposomes as their delivery 
vehicle, Alnylam and Protiva were the first group to 
demonstrate the effective targeted delivery of a siRNA, 
targeting the apoB gene in the liver of monkeys. Sirna, a 
leading pharmaceutical company in the design of antisense 
agents, also work on the design of lipid nanoparticles that 
change under certain biological conditions, such as a 
change in pH, which leads to disruption of the endosomal 
membrane setting the antisense molecule free (Arnaud, 
2006). Nastech, on the other hand, used peptide carriers as 
a delivery method, whereby a siRNA is directly 
conjugated to a peptide. The siRNA is synthesised as a 
slightly longer version (around 25-30 nucleotides) so that 
it can act as substrate for Dicer. As a result, following 
delivery, the peptide moiety is cleaved by Dicer, which 
concomitantly frees the siRNA molecule allowing it to be 
incorporated into RISC for gene silencing (Arnaud, 2006). 
Various other types of targeting ligands are also being 
investigated, such as the use of fusion proteins (e.g. 
antibody-protamine fusion protein complexed to siRNA, 
for delivery and targeting of siRNAs; Song et al, 2005) 
and aptamers. A recent study showing promising results in 
xenograft models demonstrated the use of an aptamer 
conjugated to siRNA via a double stranded RNA linker, 
for the targeting of prostate cancer cells. The aptamer used 
was specific for PMSA, a receptor that is overexpressed 
and internalised in prostate cancer cells, while the siRNA 
was used to silence survival genes overexpressed in cancer 
cells. Incubation of the aptamer-siRNA complex in cells 
expressing PMSA, led to internalisation of the complex 
and subsequent incorporation of the siRNA into the RNAi 
pathway, ultimately leading to targeted gene silencing and 
cell death. The aptamer-siRNA complex, however, did not 
bind or function in control cells that didn’t express PSMA. 
Furthermore, the antisense complex also inhibited prostate 
tumour growth in xenograft models (McNamara et al, 
2006). In another, recent, application of aptamers coupled 
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to a short hairpin RNA (shRNA), these constructs have 
demonstrated dose-dependent inhibition of RNAi by 
theophylline. To achieve this, the aptamer was coupled to 
the loop region of shRNA designed to silence fluorescent 
reporter genes and, by changing its conformation upon 
binding to theophylline, conferred the ability to modulate 
gene expression in a theophylline dependent manner (An 
et al, 2006). In a similar approach to this, though using 
antisense oligonucleotides, has also been used to modulate 
gene expression based on aptamer recognition of a target 
molecule. In this approach, modular riboregulators or 
antiswitches were designed to regulate expression of target 
transcripts as a response to ligand binding. The 
riboregulators use an antisense domain to control gene 
expression and an aptamer domain to recognise the 
specific regulating ligand. Ligand binding to the aptamer 
induces conformational changes that allow the antisense 
domain to interact with the target mRNA to affect 
translation, thus controlling translation (Bayer and 
Smolke, 2005). 
Although siRNAs have entered clinical trials against 
various other diseases, such as HIV, asthma and age-
related macular degeneration, currently no clinical trials 
for cancer have been established. 
 
4. Ribozymes and DNAzymes 
Ribozymes (RNA enzymes) are RNA molecules 
capable of catalysing the cleavage of either their own 
RNA or other RNA substrates (Tang and Breaker, 1997). 
Many naturally occurring ribozymes exist, of these RNAse 
P and the hammerhead ribozyme have been extensively 
studied (with their structures being widely used as a 
foundation for engineering other ribozymes; see below). 
RNAse P catalyses the cleavage of precursor tRNAs 
leading to their maturation. Conversely, hammerhead 
ribozymes are mostly self-cleaving enzymes (Khan, 2006). 
The principal structure of these enzymes consists of a 
catalytic motif flanked by substrate binding domains. The 
substrate-binding domain entails a sequence antisense to 
the target mRNA, allowing the enzyme to hybridise 
specifically to its substrate by Watson-Crick base pairing. 
This brings the RNA substrate close to the catalytic 
domain, which cleaves the substrate at a specific site 
recognised by the ribozyme (Famulok and Verma, 2002). 
The mechanism of catalysis undertaken by these RNA 
enzymes is a 2' oxygen nucleophile attack of the adjacent 
phosphate in the RNA backbone, leading to the formation 
of 2', 3'-cyclic phosphate and 5' hydroxyl terminus (Khan, 
2006). The resultant products are subsequently degraded 
by ribonucleases, guaranteeing permanent inactivation of 
the target. Following cleavage, the ribozyme is able to 
dissociate itself from the RNA products and bind to 
another RNA molecule to be cleaved. The significant 
advantage of ribozymes over other pharmaceutical 
reagents stems from their enzymatic property of recycling. 
Ribozymes can be potentially synthesised to target 
almost any RNA sequence. By incorporating the catalytic 
domain of ribozymes into short oligonucleotides, antisense 
to any gene of interest (i.e. changing the sequence of the 
substrate recognition domains), highly specific enzymes 
have been engineered. For example, Angiozyme targets 
the vascular epidermal growth factor receptor and is 
currently being used in clinical trials to treat metastic 
colorectal cancer. Another ribozyme in clinical trials to 
treat breast and ovarian cancer is Herzyme, used to target 
human epidermal growth factor 2 (HER2) (Zaffaroni and 
Folini, 2004). Therefore, the application of RNA cleaving 
enzymes in suppressing the expression of a range of 
therapeutically relevant genes has shown considerable 
promise. However, as with other oligonucleotide based 
therapeutics, limitations such as the mode of delivery, 
target site identification and accessibility, cleavage 
efficiency and in vivo stability of ribozymes need to be 
addressed. Chemical modification of ribozymes offers the 
potential of overcoming such problems. For example, the 
use of phosphorothioate nucleotides in ribozymes 
considerably improves their nuclease stability (Pan and 
Clawson, 2006). However, such modifications often 
dramatically reduce the catalytic activity of the enzymes. 
Alternatively, a more “natural” approach is to use DNA 
based enzymes, as DNA are less sensitive to nucleases 
than RNA. DNAzymes are DNA backbone based enzymes 
capable of specifically cleaving RNA targets. Their 
structure (catalytic domain and two substrate binding 
domains) and mechanism of catalysis is analogous to 
ribozymes (for examples of DNAzymes targeting cancer 
related genes see Dass, 2006). DNAzymes are developed 
by in vitro selection as they are not known to exist 
naturally (Dass, 2006). Hence, ultimately DNAzymes (and 
engineered ribozymes) can be considered as catalytic 
DNA aptamers. As with ribozymes, DNAzymes suffer 
from the same drawbacks which hinder their therapeutic 
application. Conversely, these small molecules are being 
successfully applied as signalling molecules in the 
diagnostic field of research and medicine (see below). 
 
B. Aptamer-based molecules for 
diagnostics 
The accurate detection of cancer markers in blood 
and tissue is a matter of increasing importance in the early 
diagnosis and thus, the treatment of cancer. The versatility 
of aptamers is exemplified in their diagnostic application 
as biosensors. Their exploitation in this field stems from 
the ability of some aptamers to undergo conformational 
changes upon ligand binding. Combined with their high 
affinity and specificity for their target, aptamers can be 
efficiently used to produce signals in response to the 
binding of a ligand in two ways: i) the direct use of 
aptamers conjugated to dyes, so that they themselves 
detect and produce the response signal (i.e. as 
molecular/aptamer beacons), or ii) the conjugation of 
aptamers to a secondary biomolecule, which produces the 
signal response (i.e. as aptazymes). 
 
1. Molecular/aptamer beacons 
Molecular beacons (MB) are single stranded 
oligonucleotide probes used to detect the presence of 
target oligonucleotides (Tyagi and Kramer, 1996). These 
molecules are designed to form hairpin structures, with the 
loop region designed to contain a complementary 
sequence to the pre-determined sequence of the target 
(Figure 2). The stem structure is composed so that ends of 
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the oligonucleotide interact with each other. At either end 
of the stem, a fluorophore and its complementary quencher 
is covalently attached. The hairpin structure of MB is 
designed so that the fluorophore and quencher stay in 
close proximity to each other, leading to the quenching of 
any fluorescence that may be emitted by the fluorophore 
by means of fluorescence resonance energy transfer 
(FRET). In the presence of its target, the loop region of 
MB hybridises in a sequence-dependent manner to the 
oligonucleotide target, which in turn causes 
conformational changes in the MB. Such ligand-induced 
conformational changes cause destabilisation of the 
hairpin and the stem region to separate. This results in the 
spatial separation of the fluorophore and quencher, 
resulting in a loss of FRET and a readily detectable signal 
(Vet et al, 2002; Rajendran and Ellington, 2003; Tan et al, 
2004). Ultimately, MB are designed to act like switches, 
where in the absence of their target they are normally 
switched off (i.e. in the hairpin state), while in the 
presence of their target they are switched on (i.e. duplex 
structure forms between target and loop region of MB and 
destabilises the stem). These signalling molecules are thus 
ideally suited to function in diagnostic assays. Indeed, MB 
have found a variety of applications such as in real time 
PCR, in vivo gene expression analysis and RNA-DNA 
interactions (Stewart, 2005), with each MB being designed 
to meet the needs of its application. MB assays offer the 
advantage of having low background signal and high 
specificity, as these probes are able to discriminate 
between two targets that differ only by a single nucleotide 
(Potyrailo et al, 1998). However, this specificity is only 
directed towards oligonucleotides targets as their ability to 
detect other analytes is limited. Their inability to detect 
proteins in particular has largely prevented their universal 
use in diagnostic assays. The conceptual framework of 
MB has, however, been applied to function for more 
versatile targets and this, not surprisingly, exploits the use 
of aptamers. Aptamer beacons (AB) combine the 
exceptional signal transduction mechanism of MB and the 
high specificity and affinity of aptamers for proteins. 
While labelled aptamers can be used as substitutes for 
antibodies in diagnostic platforms such as ELISAs and 
western blots, one powerful application is as AB. 
Although many aptamers undergo ligand-dependent 
conformational changes, they can also be engineered to 
undertake such transformations so that they efficiently 
function as AB. Adding complementary nucleotides 
conjugated to a fluorophore and quencher onto the 5’ and 
3’ end of the anti-thrombin aptamer, permitted the 
engineering of an AB designed to detect thrombin. In the 
absence of thrombin, the nucleotides at the 5’ and 3’ end 
form a duplex which forces the AB to adopt a stem loop 
structure and destabilises the native binding structure of 
the aptamer. This non-native state thus exists as a 
quenched hairpin in the absence of its target. In the 
presence of thrombin, the native aptamer structure is 
adopted and stabilised by ligand binding, which ultimately 
results in the separation of the fluorophore and quencher 
molecules leading to the concomitant increase in 
fluorescence (Hamaguchi et al, 2001). Other AB, most 
using the anti thrombin aptamer as a model, have also 
been developed by either modifying the conceptual 
framework of the beacon, i.e. quaternary structure, or the 
signalling method employed to transduce ligand binding 
into a signal (see Nutiu and Li, 2004; Wang et al, 2005 for 
overviews of different AB/MB designs). An AB for the 
detection of TAT (HIV protein) was designed, where the 
anti-TAT aptamer was split into two pieces, with one 
piece being converted into a MB. In the presence of TAT, 
reassembly of the anti-TAT aptamer pieces was promoted 
leading to the opening of the AB piece and the generation 
of a fluorescent signal (Yamamoto and Kumar, 2000). 
Potyrailo and colleagues immobilised in 1998 the anti-
thrombin aptamer onto a glass support which allowed the 
sensitive transduction of thrombin concentrations into 
changes of fluorescence anisotropy. AB for the platelet 
derived growth factor (PDGF) have also been developed 
using various fluorophore-quencher pairs, and each one 
being successful in the sensitive detection of PDGF.
 
 
 
 
Figure 2. Structure and mechanistic function of molecular beacons. In the closed state, molecular beacons (MB) exist as hairpin 
structures with the fluorophore and quencher being in close proximity and thus fluorescence being quenched. In the presence of its 
target, binding to the loop region causes the destabilisation of the duplex region of the MB which in turn causes the spatial separation of 
the reporter molecules, ultimately leading to fluorescence emission. 
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Sensitivity of the AB was such that as little as 10 ng 
PDGF per !g of serum proteins from cell culture media 
could be detected (Vicens et al, 2005). The ability to use 
AB with different FRET pairs highlights the potential that 
multiple AB for selected targets can be engineered with 
different FRET pairs and consequently used in multiplex 
bioassays (Vicens et al, 2005). Quantum dots have also 
been engineered into AB as substitutes for the 
fluorescence-quencher pairs. Quantum dots hold many 
advantages over standard fluorophores, such as being 
more photostable, having longer fluorescence lifetimes, 
sharper emission bands and although they all respond to 
the same excitation wavelength, their emission 
wavelengths differ. In one study, the anti-thrombin 
aptamer was conjugated to a quantum dot and another 
oligonucleotide, designed to hybridise and destabilise the 
aptamer structure, was conjugated to a quencher. Binding 
of thrombin led to the stabilisation of the native 
quadruplex structure of the aptamer, which caused the 
displacement of the quencher-oligonucleotide and the 
concomitant increase in fluorescence. Quantum dot based 
AB also have the potential to be used in multiplex assays. 
The fact that different quantum dots have different 
emission wavelengths, even with the wavelength for 
excitation being the same, allows multiple targets to be 
screened by appending different quantum dots onto 
different aptamers (Levy et al, 2005). Although AB offer a 
sensitive and versatile method into target detection, their 
engineering is significantly challenged by the fact that a 
detailed knowledge of the aptamer sequence and structure 
is required. MB based assays are also liable of producing 
false positive results under certain unexpected conditions. 
For example, the duplex structure formed between the 
target and MB (or AB) loop could be forced to dissociate 
under conditions such as low metal ion concentrations, 
changes in temperature or denaturing reagents (Nutiu and 
Li, 2004). The susceptibility of these beacon molecules 
towards nucleases in biological samples also needs to be 
considered. The progressive research into aptamers 
themselves will not only help to overcome the challenges 
associated with MB/AB but also facilitate the development 
of other aptamer-based signalling molecules, such as 
aptazymes, which function using an alternative method of 
signal transduction-enzyme catalysis. 
 
2. Aptazymes/Riboreporters 
The ability of enzymes to modify the intrinsic 
property of a substrate to one representative of the 
product(s) makes them powerful molecules in producing 
signal changes/response. For example, if a substrate has an 
absorbance that differs from that of the cleaved products, 
then a simple assay for substrate detection can be devised 
(where either a decrease in substrate absorbance or 
increase in product absorbance is monitored). 
Furthermore, many enzymes can be allosterically 
regulated, where an effector (such as ions, nucleotides, co-
factors, proteins) can either activate or inhibit the activity 
of an enzyme by binding to it. Effector binding usually 
induces conformational changes in the enzyme which in 
turn influences its activity. Hence, enzymes can be 
employed to either detect the presence of its substrate or 
the effector which regulates its activity, by simply 
measuring the signal from substrate cleavage. Ligand-
induced conformational changes have been shown with 
aptamers and this property has conveniently been 
engineered into ribozymes, yielding sensitive biosensors 
called aptazymes (or RiboReportersTM). Aptazymes are 
synthesised by appending an aptamer, specific for a 
ligand, to a ribozyme via a linker (or “communication 
module”; see Figure 3). In this way, interaction of the 
ligand (or effector) with the aptamer is coupled to the 
ribozyme, via the communication module, by either 
activating or inhibiting the enzyme activity (Kertsburg and 
Soukup, 2002; Silverman, 2003). Hence, the 
conformational adaptability of aptamers permits the 
allosteric regulation of ribozyme activity, as in nature, 
allosteric regulation of ribozymes has not yet been 
identified (Silverman, 2003). 
 
 
Figure 3. Schematic composition 
and function of an aptazyme. 
Aptazymes are typically made by 
conjugating an aptamer to a 
ribozyme via a communication 
module. Effector binding induces 
conformational changes in the 
aptamer, which is relayed to the 
ribozyme via the communication 
module. The change in ribozyme 
activity (by either upregulation or 
downregulation), as a result of 
effector binding, can then be 
monitored by suitable methods. 
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Although small peptides have been known to 
increase ribozyme activity, the extent of activation 
compared to basal activity is relatively small. Conversely, 
upon conjugation of an aptamer, ribozyme activity has 
shown to be greatly facilitated by an effector, typically 
between 10 to 103-fold (Silverman, 2003). Aptazymes also 
show exceptional specificity for their effectors, whereby 
they are able to discriminate between small differences in 
functional groups and protein isoforms, primarily owing to 
the aptamer domain. When conjoined, the specificity of an 
anti-theophylline aptamer has shown to be conferred to a 
theophylline aptazyme. Although a modest 18-fold 
activation in aptazyme activity was observed in the 
presence of theophylline, no activation was prevalent in 
the presence of caffeine, a molecule which differs by only 
one methyl group (Thompson et al, 2002). The 
theophylline-induced aptazyme has also been used in the 
design of an aptazyme-based riboswitch that can offer a 
detector-free and label-free detection of aptamer binding 
to its target, through the expression of the gene of a 
reporter protein (Ogawa and Maeda, 2007). In this work, 
the whole construct of aptazyme, ribosome-binding site, 
anti-ribosome-binding site, necessary stem loops and 
reporter gene are included in a DNA template that, during 
transcription results in a conformation that does not allow 
ribosome binding and expression of the reporter protein. 
However, binding of the cofactor theophylline induces 
conformation changes that results in ribosome binding and 
expression of the reporter protein. Subsequent detection of 
the reporter protein levels corresponds to cofactor binding 
to the aptazyme (Ogawa and Maeda, 2007). 
Aptazymes modified with a fluorescence based 
signalling system have also been engineered and such 
molecules have been designated RiboReportersTM. An 
ADP aptamer appended to the core unit of a hammerhead 
ribozyme with an integrated fluorescent-quencher system, 
showed ADP-dependent ribozyme self cleavage, which led 
to the release of the quencher and the generation of a 
fluorescent signal in the presence of ADP. This 
RiboReporterTM was able to specifically discriminate 
between ADP and over 100-fold molar excess of ATP, 
demonstrating the exceptional specificity of the aptamer 
domain (Srinivasan et al, 2004). Ferguson and colleagues 
also generated in 2004 fluorescence based RiboReporterTM 
sensors able to detect caffeine or aspartame. The 
aspartame RiboReporterTM demonstrated exquisite 
specificity whereby ribozyme activity was facilitated 50-
fold by aspartame, while it remained unaffected in the 
presence of the closely related molecules, "-aspartame and 
phenylalanine. The function of aptazymes fundamentally 
entails conformational changes in the aptamer domain 
upon effector binding, which via the communication 
module, leads to changes in ribozyme activity. However, 
the detailed coupling mechanism of effector binding to 
ribozyme activity is yet unknown, although it is generally 
postulated that the aptamer-ligand complex stabilises the 
structurally active conformation of the ribozyme 
(Robertson and Ellington, 1999; Najafi-Shushtari and 
Famulok, 2005). 
The remarkable utility of aptazymes as biosensors 
stems from their ability to act as molecular switches 
whereby enzyme activity can be turned on or off in 
response to the target being screened (i.e. effector/ligand 
for the aptamer domain). This has been demonstrated by 
the Ikebukuro group, who measure thrombin activity 
based on the ability of the construct to change 
conformation upon binding to the ligand for detection, 
whether a small molecule, such as adenosine (Yoshida et 
al, 2006a) or a complementary piece of DNA (Yoshida et 
al, 2006b). Furthermore, combining the multiple turnover 
activity of ribozymes with the high specificity and affinity 
of aptamers, allows the engineering of biosensors with 
unique sensitivity. That is to say, signal (i.e. the response 
to effector detection) amplification can be easily achieved 
even at low effector/target concentration, by serial addition 
of the substrate (RNA) which enhances catalytic turnover 
(Cho et al, 2005). Consequently, the combined advantages 
offered by both the aptamer and ribozyme domain, allows 
for aptazymes to be used as efficient substitutes for 
antibodies in assays used to detect specific disease related 
makers. Aptamer-based sensors overcome many of the 
drawbacks associated with the use of antibodies (see 
below) for the detection of proteins. In addition, the use of 
aptazyme-based assays omits the use of other secondary 
molecules typically used to produce the signal, such as 
secondary antibodies used in ELISAs. 
The aptazyme approach to diagnosis can, in 
principle, be applied to any marker for any disease if 
aptamer selection towards the target is achieved. 
Furthermore, the unique ability to select aptamers binding 
to any molecule allows the application of aptazymes as 
sensors to be extended outside the field of medical 
diagnosis. Such an attribute is not available in many 
antibody-based assays, which are only employed in the 
biomedical field. For example, aptamer-based assays can 
be used as environmental sensors whereby they are 
applied to detect persistent pollutants (such as heavy 
metals or explosives) in soil and water. Although 
aptazymes show promising potential as biosensors, the 
problems associated with their engineering has hindered 
their success. One of the main problems associated with 
all aptamer-based modifications, is that it is often difficult 
to maintain the binding affinity of the aptamer towards the 
target. The catalytic activity of the ribozyme unit can also 
be affected by conjugation of the aptamer. Moreover, the 
innate self-cleaving activity of ribozymes sometimes 
causes a high background signal (Araki et al, 1998; 
Kertsburg and Soukup, 2002; Cho et al, 2005). However, 
this challenge can be overcome by the engineering of an 
aptazyme which can be allosterically regulated by an 
inhibitory molecule and an allosteric activator. The hairpin 
ribozyme consists of two domains which together form a 
catalytic complex when in the correct conformation. The 
introduction of an FMN aptamer domain into the ribozyme 
was shown to facilitate catalysis upon formation of the 
FMN-aptamer complex. Alternatively, in the presence of 
an oligonucleotide complementary to the aptamer domain, 
ribozyme activity was completely abolished. In the 
presence of FMN, however, a 150-fold increase in activity 
was observed (Najafi-Shoushtari and Famulok, 2005). 
Hence, hybridisation of the small inhibitory 
oligonucleotide can ultimately be employed to reduce 
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background signal. In addition, other complications 
associated with all aptamer-based technologies, such as 
nuclease sensitivity, cost-effectiveness and non specific 
binding of RNA binding proteins in biological fluids need 
to be considered before the practical application of such 
molecules is achieved. 
 
3. Aptamers microarrays 
Oligonucleotide microarrays have been used for 
genomic applications for some time with interesting 
results. Their widespread use for monitoring gene 
expression has generated valuable insight into various 
disease states, analysing gene clusters and revealing 
polymorphisms. Aptamers, usually oligonucleotides in 
nature, have also the ability to be used in microarrays and 
have recently found their way into the microarray 
scientific literature and market. Different aptamer 
microarrays with varying detection systems have been 
described. The basic principle lies on the spotting of 
oligonucleotide aptamers, RNA or DNA on a surface / 
chip, the interaction of the aptamers with the analyte 
containing the target molecule, and the detection of the 
bound oligonucleotides/aptamers by some physical 
method. 
One such application of the traditional nucleic acid 
microarray technology to aptamers has been described by 
Ellington (Collett et al, 2005; Cho et al, 2006). In this, 
aptamers against specific target molecules, such as 
thrombin, lysozyme, ricin or IgE have been printed on 
streptavidin or neutravidin coated glass slides. The total 
protein content of a cell or a biological medium is that was 
to be analysed was fluorescently labelled and the analyte 
solution was incubated with the aptamers on the array. 
Following washes to eliminate non-binding and non-
specific binding proteins from the array, the bound 
molecules were detected. The array was shown to be 
particularly sensitive, allowing detection of proteins in the 
low picomolar to nanomolar range (Collett et al, 2005; 
Cho et al, 2006). Furthermore, this indicated that multiple 
protein analytes can be identified simultaneously. This has 
been stipulated to have great potential in proteomic 
applications. However, this could equally have substantial 
applications in diagnostic arrays, where, for example, 
aptamers against multiple tumour markers could be printed 
on the slide, allowing simultaneous measurement of 
various tumour marker levels for better cancer 
prognosis/early diagnosis. 
A similar approach on aptamer microarrays that 
differs on the detection method is based on enzymatically 
amplified surface plasmon resonance imaging (SPRI) 
detection of protein biomarkers in aptamer microarrays. 
SPRI is perhaps one of the primary optical methods for the 
detection of affinity adsorption onto biomolecular 
microarrays, including oligonucleotide (DNA and RNA) 
and protein arrays. However, enzymatic amplification of 
the signal can further enhance the sensitivity of the assay. 
This is a sandwich format, where the aptamers are dotted 
in the array, the protein is allowed to interact with the 
aptamer, followed by several washes and that is exposed 
to a protein-specific antibody-horseradish peroxidase 
(HRP) conjugate. An HRP substrate is then used to create 
a localised precipitation reaction that amplifies the SPR 
signal (Li et al, 2006, 2007). This enzymatically enhanced 
SPR sensor has demonstrated the ability to also detect 
multiple analytes, though still at an early stages and not 
tested in biological fluids as the fluorescent detection 
microarrays, working only with multiple purified protein 
samples. However, in these experiments it has 
demonstrated superior detection capabilities. The 
fluorescent detection microarray has been reported to 
detect thrombin in a solution at a 5nM concentration (Cho 
et al, 2006), whereas the enzymatically enhanced SRPI 
sensor has shown a detection limit for thrombin of 500fM 
(Li et al, 2007); a tenfold improved limit of detection. On 
the other hand, the enzymatically enhanced SPRI is based 
on the assumption that there is a second binding site on the 
molecule which is recognised by a HRP-conjugated 
antibody in a sandwich assay. This would not apply to 
small molecules or peptides, where the aptamer covers the 
entire, or the majority of the analyte, leaving little or 
nothing to be recognised by the antibody part, or where the 
aptamer would substantially change the structure of the 
target molecule upon binding, thus inhibiting secondary 
interactions with the antibody. Furthermore, this implies 
that such technology would not take advantage of the 
ability of aptamers to bind to non-immunogenic ligands 
where antibody development is a difficult, if not 
impossible task. 
SPRI detection in microarrays has also been used 
with peptide aptamers. However, like most protein 
microarrays, this is a more complicated task than using 
DNA microarrays, which is now a standard technology. 
Yet, peptide aptamer microarrays have achieved a 
sensitivity of 1nM for their target protein (Davis et al, 
2007) and, though still in its infancy, may yet prove to be 
an interesting alternative in the microarray detection 
technology. 
 
4. Photoaptamers 
One of the potential diagnostic applications of 
aptamers in the area of proteomics and linked with the 
development of the aptamer microarrays discussed above 
is the concept of photoaptamers, developed and 
championed by SomaLogic Ltd, one of the major players 
in the aptamer technology development. Though 
photoaptamers are also used in a microarray format, to 
allow for detection of multiple analytes, it does not use 
previously developed aptamers and varying the detection 
methodology. Instead, it is based on a different approach 
and a modified selection process, named PhotoSELEX. 
In photoaptamer libraries, the tymidine (T) of normal 
DNA is substituted, usually, by 5-bromo-2’-deoxyuridine, 
which confers to the aptamers the capability of 
crosslinking to specific sites of the protein analyte, 
particularly on tyrosine residues, when exposed to UV 
light. This has allowed a modified selection process, in 
which oligonucleotides that do not crosslink with the 
protein are eliminated from the pool, whilst those that bind 
and crosslink are subsequently amplified in a fashion 
similar to the traditional SELEX methodology. Thus, like 
in the normal SELEX, photoaptamer libraries containing 
5-bromo-2’-deoxyuridine instead of thymines are exposed 
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to the target of interest. Oligonucleotides that do not bind 
or bind only weakly to the target are washed away in the 
various wash steps. Here, in contrast with the normal 
SELEX, what remains bound is exposed to UV radiation 
which facilitates crosslinking of the aptamer to the target 
through the formation of a covalent bond between the 
modified base and an appropriate amino acid (usually 
tyrosine) that is in close proximity to the binding site. 
Oligonucleotides that do not crosslink are also washed 
away. To amplify the bound aptamers by PCR, crosslinked 
proteins are digested by proteases to reveal the aptamers 
(www.somalogic.com). The photoSELEX process is 
described in Figure 4. 
Once selected, photoaptamer can be used in 
microarray formats, for proteomic applications, exhibiting 
a specificity ranging from 100 to >106 fold for the target 
proteins over non-specific proteins, with usual values in 
the 104 range (Smith et al, 2002). Examples of 
photoaptamers in proteomics multiplex photoaptamer-
based arrays have been described successfully and have 
been presented for protein analytes such as interleukin 16 
(IL-16), vascular endothelial growth factor (VEGF) and 
endostatin, with unparalleled sensitivity. The sensitivity 
reported for such aptamers reaches a detection limit of 
10fM, the lowest detection limit reported in the current 
aptamer microarray technologies (Bock et al, 2004). Even 
so, photoaptamers have not yet achieved their potential, 
with only a handful of publications in the literature and no 
known significant developments. Various potentially 
limiting factors may include the fact that appropriate 
amino acids need be close to the binding site of the 
aptamers to affect crosslinking, or else no hits will be 
achieved given the nature of the photoSELEX 
methodology. Furthermore, this technology would not 
benefit from the multitude of selected aptamers from 
various groups around the world and photoaptamers for 
each target would need to be generated. Finally, the strong 
intellectual property control of SomaLogic prohibits other 
companies to show an interest in the diagnostic 
applications of aptamers in general and photoaptamers 
specifically. 
 
5. Aptamers vs Antibodies 
It is far from realistic to suggest that aptamers could 
replace the role of antibodies in diagnostics. However, 
aptamers do represent a valuable and viable 
complimentary technology that as yet appears to have 
gone unnoticed by all but a handful of research groups. 
Claims around aptamers have been that they offer 
marvellous advantages over their antibody counterparts. 
Yet, while not everything is the way the Gurus would have 
us imagine, aptamers have both advantages and
 
 
 
 
Figure 4. A schematic description of the photoSELEX process (www.somalogic.com). 
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disadvantages over their older and larger protein relatives. 
Aptamer recognition affinity and specificity is comparable 
to those of monoclonal antibodies, and sometimes higher, 
as aptamers are selected for high affinity, whilst nature 
often prefers more reversible interactions. Furthermore, 
aptamers can be selected to recognize and bind a wide 
range of targets, including toxic compounds, toxins and 
drug molecules, as well as inherently non-immunogenic 
molecules that antibodies cannot be raised against 
(Jayasena, 1999). Such examples include ricin and cocaine 
which has been a target in sensor development, as we saw 
above (Stojanovic et al, 2001; Stojanovic and Landry, 
2002; Baker et al, 2006; Cho et al, 2006). 
Aptamers can act as mimics of antibodies in that they 
can recognise molecular targets with high specificity and 
are able to carry therapeutic agents, fluorescent or MRI 
agents, radioisotopes, etc, directly to solid tumour masses 
or to individual cells that may have metastasised with 
greater efficiency (Brody and Gold, 2000; Cerchia et al, 
2002; Ferreira et al, 2006; Borbas et al, 2007), thus 
offering great potential in diagnostic imaging. 
Furthermore, as aptamers are 10 to 100 times smaller than 
antibodies, they are expected to achieve higher tumour 
penetration than their counterparts. 
When compared to antibodies, aptamers have 
advantages and disadvantages as therapeutic and 
biological reagents (Jayasena, 1999). Aptamers present 
faster tissue penetration and wider applicability and 
present the opportunity for simple base modifications to 
improve functionality by comparison. Furthermore their 
small size (molecular weights between 3000-20000) may 
reduce steric hindrance and increasing surface coverage 
during immobilization on chromatography matrices (Deng 
et al, 2001), sensors or immunoassays (Ferreira et al, 
2008). The in vitro selection process (SELEX) can be 
more precisely monitored than can organismal 
immunization, and the affinities and specificities of 
aptamers can thus be better tailored than can those of 
antibodies (Jayasena, 1999). And yet, as antibody 
technology continues to evolve, one of the basic 
advantages often discussed with regards to aptamer, the 
one of their in vitro generation compared to antibodies’ 
generation within an organism, is getting minimised. 
Antibody production technologies, such as the SLAM 
technology used by UCB (www.ucb-group.com), can also 
result in the raising of antibodies outside animals and the 
use of hybridomas. This technology, however, still 
exploits the use of living cells, which does not alter the 
fact that antibodies could not be raised to toxic chemicals. 
One of the main advantages of aptamers is that, once 
identified, they can be reliably synthesized by automated 
methods, reducing batch to batch variations. Furthermore, 
during synthesis, aptamers can be easily modified to 
facilitate further modifications such as attachment points 
for enzymes or a variety of other reagents, and the 
introduction of modified bases for nuclease resistance 
(Figure 5) (Eaton et al, 1997; Gewirtz, 1999; Brody and 
Gold, 2000). 
Aptamers can be stored for long term and transported 
in ambient temperatures, which gives them an advantage 
on thermal stability over their antibody counterparts, and 
are resistant to denaturation and degradation when 
lyophilised. Furthermore, in sensors and chips can be 
successfully regenerated, unlike most antibody arrays. 
However, aptamers are sensitive to nucleases, which 
presents a problem on diagnostic assays based on the assay 
of disease markers in biological fluids. The above 
mentioned modification of aptamers prolongs their 
lifetime on the sensor and their resistance to nucleases, but 
mostly delays rather than completely averts their 
degradation. 
 
 
 
 
Figure 5. Possibilities for chemical modification of a nucleotide base 
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Finally, although aptamer production costs are lower 
than those of an antibody and aptamers can generally be 
produced faster than antibodies, the price of aptamer 
synthesis still remains much higher of their protein 
counterparts. This is largely due to the fact that antibody 
production technologies have been around for much longer 
and the need for large amounts of antibodies have pushed 
technological developments in the area. Instead, only a 
handful of aptamers have been produced at large enough 
scale for clinical trials and diagnostic applications to 
warrant production in gram scale. Thus, the technological 
focus of oligonucleotide synthesis is limited to small scale 
experiments for laboratory use. Companies like Pfizer that 
are now producing the only aptamer in the clinic and 
Antisoma that are currently conducting clinical trials on 
aptamers as cancer therapeutics, with the need of large 
quantities of the therapeutic preparation, are pushing the 
current technological limits for large scale aptamer 
synthesis. Yet, a number of pharmaceutical and biotech 
companies do not yet consider aptamers as valuable 
reagents due to prohibitive costs and a technology that is 
not yet robust enough. Finally, the complex Intellectual 
Property scene on aptamers and the proprietary technology 
for aptamer production, SELEX, spreads further 
scepticism over the use of aptamers in diagnostic 
applications. Yet, with the original patents on SELEX and 
aptamer production expiring in the next few years, this 
field remains open and ripe for further exploitation. 
Overall, aptamers and their related biomolecules are 
still in an early stage of development for therapeutic and 
diagnostic purposes. They do however, clearly 
demonstrate their versatility in potentially binding a 
plethora of targets, hence they can find application to 
fields outside medicine, a benefit that antibodies have not 
yet overcome. Within the medical field itself, aptamers 
offer many significant advantages that cannot be dismissed 
and as such they can rival antibodies on some assays or 
work with them in others. 
 
III. Concluding remarks 
It is undeniable that aptamers offer a great potential 
for diagnostic and sensor applications and these bypass 
some of the problems nucleic acid based agents face as 
therapeutic and clinical agents. The SELEX procedure has 
offered the possibility to develop aptamers against any 
kind of target, whilst subsequent technologies for aptamer 
selection have offered alternatives and improved such 
selection processes in cost, time or project specific 
requirements. Photo-SELEX (www.somalogic.com) has 
promised potential developments in the field of 
proteomics, whereas SELEX NADIR has offered similar 
capabilities with photo-SELEX, but with the use of a 
nanopore reporting mechanism instead of the optical probe 
reporting one (Winters-Hilt, 2006). However, due to IP 
restrictions, the commercial applications of these agents 
are still limited. Thus, very few aptamer microarrays are 
currently in development from companies like Affymetrix, 
and one is currently in the market by LC Sciences, which 
contains 1,500 aptamers against various targets of interests 
from the published literature (www.lcsciences.com). On 
the other hand, photoaptamers 
Apart from microarrays, a number of other sensor 
applications have been pursued by various academic and 
commercial groups. The Archemix group, which have 
developed fluorescent microarrays described above, have 
also used fluorescent aptamers in chips and microspheres 
(Potyrailo et al, 1998; Kirby et al, 2004). Other groups 
have also used fluorescent detection sensors based on 
aptamer technologies to recognise small molecules, such 
as L-arginamide (Ozaki et al, 2006) and ATP (Yamana et 
al, 2003). A novel application of fluorescent aptamer 
detection is with the use of quantum dots and a few 
applications have recently appeared in the literature. The 
ability of different quantum dots to emit at different 
wavelengths whilst excited at the same wavelength could 
offer a solution for multiple analyte detection in solutions, 
as demonstrated for adenosine and cocaine by Liu and 
colleagues in 2007. Quantum dot use with aptamers for 
detection of protein analytes has also been described 
(Levy et al, 2005; Choi et al, 2006), as well as detection of 
bacillus spores (Ikanovic et al, 2007), which further 
demonstrates the flexibility of these constructs. 
Apart from fluorescence, a number of other sensor 
detection methodologies have been adopted with varying 
degrees of success. These include colorimetric changes 
(Liu and Lu, 2004, 2006; Cho et al, 2005), electrochemical 
detection (Xiao et al, 2005; Mir et al, 2006; Lai et al, 
2007; Papamichael et al, 2007) and piezoelectric quartz 
crystal sensors (Bini et al, 2007). 
The above methods, fluorescent, electrochemical and 
colorimetric detection, have also been used in a number of 
molecular switch approach sensors or modular sensor 
assemblies, where the aptamers usually change 
conformation upon binding to either emit a fluorescent 
signal based on an approach similar to an aptamer beacon 
on sensor, where the aptamer is labelled both by a 
fluorophore and a quencher, or through non-covalent 
interaction with the fluorescent label, triggering of an 
electrochemical sensor or change of colour (Frauendorf 
and Jaschke, 2001; Stojanovic et al, 2001; Stojanovic and 
Landry, 2002; Stojanovic and Kolpashchikov, 2004; Baker 
et al, 2006; Zuo et al, 2007). These sensors have been 
shown to be particularly sensitive in recognising small 
molecules like cocaine (Stojanovic et al, 2001; Baker et al, 
2006; Zuo et al, 2007), ATP (Stojanovic and 
Kolpashchikov, 2004; Zuo et al, 2007) or theophylline 
(Frauendorf and Jaschke, 2001) with high selectivity. 
However, aptamers have been used in enzymatic 
sensing, without the use of any label or signal related 
directly to the aptamer. These applications are again based 
on changes in aptamer conformation of bifunctional 
aptamers that recognise the target ligand and an enzyme or 
ribosome. The binding of the aptamer to the ligand results 
in conformational changes that affect enzymatic activity or 
protein expression, and it is the later that is subsequently 
measured (examples in Ogawa et al, 2007; Yoshida et al, 
2006a,b). Finally, an enzymatic detection system that is 
however different in that the enzyme is used not for 
detection but to ligate proximally bound aptamers to large 
protein targets and allow their subsequent PCR 
amplification has been described. This has allowed 
detection of ligands at zeptomole (40x10-21 mol) amounts, 
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significantly reducing previously described detection 
limits (Fredrikson et al, 2002). 
The breadth of the above techniques available for 
analyte detection based on aptamer technologies has 
opened a variety of possibilities for aptamer-based sensors 
in different applications, ranging from early disease 
diagnosis and prognosis, to control of substances, such as 
anabolics and steroids in anti-doping control of athletes, or 
environmental sensors for the detection of pollutants, 
explosives or potential infectious agents, giving aptamers 
a breadth of application that has not been feasible with 
other agents to date. 
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